Androgen receptor profiling predicts prostate cancer outcome

Abstract Prostate cancer is the second most prevalent malignancy in men. Biomarkers for outcome prediction are urgently needed, so that high‐risk patients could be monitored more closely postoperatively. To identify prognostic markers and to determine causal players in prostate cancer progression, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzan Stelloo, Ekaterina Nevedomskaya, Henk G van der Poel, Jeroen de Jong, Geert JLH van Leenders, Guido Jenster, Lodewyk FA Wessels, Andries M Bergman, Wilbert Zwart
Format: Article
Language:English
Published: Springer Nature 2015-09-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.15252/emmm.201505424
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Prostate cancer is the second most prevalent malignancy in men. Biomarkers for outcome prediction are urgently needed, so that high‐risk patients could be monitored more closely postoperatively. To identify prognostic markers and to determine causal players in prostate cancer progression, we assessed changes in chromatin state during tumor development and progression. Based on this, we assessed genomewide androgen receptor/chromatin binding and identified a distinct androgen receptor/chromatin binding profile between primary prostate cancers and tumors with an acquired resistance to therapy. These differential androgen receptor/chromatin interactions dictated expression of a distinct gene signature with strong prognostic potential. Further refinement of the signature provided us with a concise list of nine genes that hallmark prostate cancer outcome in multiple independent validation series. In this report, we identified a novel gene expression signature for prostate cancer outcome through generation of multilevel genomic data on chromatin accessibility and transcriptional regulation and integration with publically available transcriptomic and clinical datastreams. By combining existing technologies, we propose a novel pipeline for biomarker discovery that is easily implementable in other fields of oncology.
ISSN:1757-4676
1757-4684